Literature DB >> 11972302

Evidence for greater oxidative substrate flexibility in male carriers of the Pro 12 Ala polymorphism in PPARgamma2.

C Thamer1, M Haap, A Volk, E Maerker, R Becker, O Bachmann, F Machicao, H U Häring, M Stumvoll.   

Abstract

The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma2 (PPARgamma2) gene is associated with reduced type 2 diabetes risk and increased insulin sensitivity. It is possible that the oxidative shift from lipid to glucose as a fuel is more efficient in Ala allele carriers. To test this hypothesis, we examined carbohydrate and lipid oxidation by indirect calorimetry in lean, glucose tolerant subjects with (X/Ala, n = 25) and without the Pro12Ala polymorphism (Pro/Pro, n = 73) basally and after insulin stimulation during a 2-hour eugylcaemic hyperinsulinaemic clamp. Insulin sensitivity was non-significantly greater in X/Ala (0.13 +/- 0.01 micromol/kg/min/pM) than in Pro/Pro (0.12 +/- 0.01 micromol/kg/min/pM, p = 0.27). Basally, there were no lipid nor carbohydrate oxidation differences between the groups. Interestingly, the decrease in lipid oxidation during insulin stimulation was significantly greater in male X/Ala (- 0.51 +/- 0.06 mg/kg/min) than in male Pro/Pro (- 0.35 +/- 0.04 mg/kg/min, p = 0.03). No difference was observed in females. Analogously, the change in carbohydrate oxidation in male X/Ala (1.34 +/- 0.2 mg/kg/min) was significantly greater than in male Pro/Pro (1.03 +/- 0.12 mg/kg/min, p = 0.05). The respiratory quotient increased more, but not significantly more, in male X/Ala (0.11 +/- 0.01) than in male Pro/Pro subjects (0.08 +/- 0.01, p = 0.08) but similarly in females. These results indicate that the mechanism by which the Ala allele improves insulin sensitivity might involve enhanced suppression of lipid oxidation permitting more efficient (predominantly non-oxidative) glucose disposal. It is unclear why this could be demonstrated only in males, although gender differences in substrate oxidation are well documented.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972302     DOI: 10.1055/s-2002-23196

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  13 in total

1.  PPARγ Pro12Ala interacts with fat intake for obesity and weight loss in a behavioural treatment based on the Mediterranean diet.

Authors:  Marta Garaulet; Caren E Smith; Teresa Hernández-González; Yu-Chi Lee; Jose M Ordovás
Journal:  Mol Nutr Food Res       Date:  2011-11-21       Impact factor: 5.914

2.  Influence of Pro12Ala peroxisome proliferator-activated receptor gamma2 polymorphism on glucose response to exercise training in type 2 diabetes.

Authors:  K B Adamo; R J Sigal; K Williams; G Kenny; D Prud'homme; F Tesson
Journal:  Diabetologia       Date:  2005-06-29       Impact factor: 10.122

3.  Improvements in glucose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: results from the HERITAGE Family Study.

Authors:  S-M Ruchat; T Rankinen; S J Weisnagel; T Rice; D C Rao; R N Bergman; C Bouchard; L Pérusse
Journal:  Diabetologia       Date:  2009-12-31       Impact factor: 10.122

4.  Meta-analysis of associations between the peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and susceptibility to nonalcoholic fatty liver disease, rheumatoid arthritis, and psoriatic arthritis.

Authors:  Young Ho Lee; Sang-Cheol Bae; Gwan Gyu Song
Journal:  Genet Test Mol Biomarkers       Date:  2014-04-03

5.  Association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma gene and strength athlete status.

Authors:  Agnieszka Maciejewska-Karlowska; Marek Sawczuk; Pawel Cieszczyk; Aleksandra Zarebska; Stanislaw Sawczyn
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

6.  The Pro12Ala Polymorphism of the Peroxisome Proliferator-Activated Receptor Gamma Gene Modifies the Association of Physical Activity and Body Mass Changes in Polish Women.

Authors:  Aleksandra Zarebska; Zbigniew Jastrzebski; Pawel Cieszczyk; Agata Leonska-Duniec; Katarzyna Kotarska; Mariusz Kaczmarczyk; Marek Sawczuk; Agnieszka Maciejewska-Karlowska
Journal:  PPAR Res       Date:  2014-10-13       Impact factor: 4.964

Review 7.  Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review.

Authors:  Xiao-Lin Li; Jian-Qing Sui; Lin-Lin Lu; Nan-Nan Zhang; Xin Xu; Quan-Yong Dong; Yong-Ning Xin; Shi-Ying Xuan
Journal:  Lipids Health Dis       Date:  2016-03-10       Impact factor: 3.876

8.  Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients.

Authors:  Limei Liu; Taishan Zheng; Feng Wang; Niansong Wang; Yanyan Song; Ming Li; Lifang Li; Jiamei Jiang; Weijing Zhao
Journal:  Diabetes Care       Date:  2009-10-16       Impact factor: 19.112

9.  Impact of the Pro12Ala polymorphism of the PPAR-Gamma 2 gene on metabolic and clinical characteristics in the Palestinian type 2 diabetic patients.

Authors:  S Ereqat; A Nasereddin; K Azmi; Z Abdeen; R Amin
Journal:  PPAR Res       Date:  2009-10-25       Impact factor: 4.964

10.  Birth weight and blood lipid levels in Spanish adolescents: influence of selected APOE, APOC3 and PPARgamma2 gene polymorphisms. The AVENA Study.

Authors:  Jonatan R Ruiz; Idoia Labayen; Francisco B Ortega; Luis A Moreno; Domingo González-Lamuño; Amelia Martí; Esther Nova; Miguel García Fuentes; Carlos Redondo-Figuero; J Alfredo Martínez; Michael Sjöström; Manuel J Castillo
Journal:  BMC Med Genet       Date:  2008-11-10       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.